Epidermal growth factor receptor as a therapeutic target in colorectal cancer

Clinical Colorectal Cancer

Volumn 2, Issue 4, 2003, Pages 246-251

  Cohen, Roger B ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

ABX EGF; Cetuximab; Erlotinib (OSI 774, Tarceva ); Gefitinib (Iressa ); Receptor tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACNE; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPETITIVE INHIBITION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; FOLLICULITIS; HUMAN; LIGAND BINDING; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; RASH; SIGNAL TRANSDUCTION; SKIN TOXICITY;

EID: 0037302445     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.006     Document Type: Article

References (56)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
3. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 2002; 21:128a (Abstract #511).
4. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma. Cancer 2001; 92:1331-1346.
5. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
6. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
7. Hemming AW, Davis NL, Kluftinger A, et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51:147-152.
8. Messa C, Russo F, Caruso MG, et al. EGF, TGF-a, and EGF-R in human colorectal adenocarcinoma. Acta Oncologica 1998; 37:285-289
9. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
10. Wells A. Molecules in focus. EGF receptor. Int J Biochem Cell Biol 1999; 31:637-643.
11. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999; 82:207-218.
12. Davies DE, Chamberlin SG. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 1996; 51:1101-1110.
13. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19:32s-40s.
14. Lawrence DS, Niu J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther 1998; 77:81-114.
15. Grotendorst GR, Soma Y, Takehara K, et al. EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J Cell Physiol 1989; 139:617-623.
16. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997; 16:750-759.
17. de Jong JS, van Diest PJ, van der Valk P, et al. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J Pathol 1998; 184:53-57.
18. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17:1595-1606.
19. Perry JE, Grossmann ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998; 35:117-124.
20. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997; 70:722-726.
21. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
22. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-250.
23. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-446.
24. Houghton AN, Scheinberg DA. Monoclonal antibody therapies-a 'constant' threat to cancer. Nat Med 2000; 6:373-374.
25. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. A new paradigm for cancer therapy. Cancer 2002; 94:1593-1611.
26. Rinehart JJ, Wilding J, Willson S, et al. A phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21:11a (Abstract #41).
27. DeSimone PA, Bence AK, Anderson EB, et al. A phase I study to investigate safety, tolerability, and pharmacokinetics of single and escalating doses of GW572016 in healthy volunteers. Proc Am Soc Clin Oncol 2002; 21:94a (Abstract #375).
28. Saltz L, Rubin MS, Hochster HS, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC- C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin Cancer Res 2001; 7(suppl):3766s (Abstract #559).
29. Saltz L, Meropol NJ, Loehrer PJ, et al. Single agent IMC- C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21:127a (Abstract #504).
30. Rosenberg AH, Loehrer PJ, Needle, MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21:135a (Abstract #536).
31. Schoffski P, Lutz MP, Folprecht G, et al. Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5-FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21:159a (Abstract #633).
32. Hammond LA, Figueroa J, Schwartzberg L, et al. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa™), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001; 20:137a (Abstract #544).
33. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995; 95:1897-1905.
34. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-3747.
35. Viloria Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am J Pathol 1997; 151:1523-1530.
36. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-264.
37. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by angiogenic mechanisms. Clin Cancer Res 2000; 6:1936-1948.
38. O-Charoenrat P, Rhys-Evans P, Modjtahedi H, et al. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 2000; 86:307-317.
39. Naramura M, Gillies SD, Mendelsohn J, et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model of human melanoma. Cancer Immunol Immunother 1993; 37:343-349.
40. Prewett M, Hooper A, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8:994-1003.
41. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85:1327-1333.
42. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18(suppl 21):47S-53S.
43. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-1176.
44. Burtness BA, Yi L, Flood W, et al. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 2002; 21:226a (Abstract #901).
45. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001; 37(suppl 4):S16-S22.
46. Cohen RB, Falcey JW, Paulter VJ, et al. Safety profile of the monoclonal antibody (MoAb) IMC- C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors. Proc Am Soc Clin Oncol 2000; 19:474a (Abstract #1862).
47. Yang XD, Jia XC, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23.
48. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002; 21:10a (Abstract #35).
49. Klohs W, Fry DW, Kraker AJ. Inhibitors of tyrosine kinase. Curr Opin Oncol 1997; 9:562-568.
50. Levitt ML, Koty PP. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 1999; 17:213-226.
51. Anderson NG, Ahmad T, Chan K, et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001; 94:774-782.
52. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
53. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
54. Finkler N, Gordon A, Crozier M, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 2001; 20:208a (Abstract #831).
55. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
56. Senzer NN, Soulieres D, Siu L, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001; 20:2a (Abstract #6).